36 results about "Biological fluid" patented technology

A biological fluid collection system that receives a sample and provides flow-through blood stabilization technology and a precise sample dispensing function for point-of-care and near patient testing applications is disclosed. A biological fluid collection system of the present disclosure is able to effectuate distributed mixing of a sample stabilizer within a blood sample and dispense the stabilized sample in a controlled manner. In this manner, a biological fluid collection system of the present disclosure enables blood micro-sample management, e.g., passive mixing with a sample stabilizer and controlled dispensing, for point-of-care and near patient testing applications.

The application relates to the technical field of free radical detection, in particular to a high-sensitivity in-situ capture and detection method of organic free radicals based on a DIPPMPO probe and application, and the method comprises the following steps: adding a chemical probe DIPPMPO into a reaction system containing potential organic free radical precursors, so that the DIPPMPO and organic free radicals generated in a reaction process occur adduct reaction to form a DIPPMPO-free radical adduct which can be detected under liquid chromatography-mass spectrometry conditions; performing high performance liquid chromatography-quadrupole-time of flight mass spectrometry analysis on a mixed solution after the adduct reaction is completed, so that first mass spectrometry data and secondary mass spectrometry fragment information of the DIPPMPO-free radical adduct are obtained; and automatically processing the secondary mass spectrometry data, screening out parent ions with continuous neutral loss as potential DIPPMPO-free radical adduct candidate signals. The application does not need derivatization, is simple to operate, is broad-spectrum and high-efficiency, and can be applied to environmental water samples, biological fluids, chemical reaction liquids or drug metabolism systems.

A biological fluid processing device includes pump and valve systems, a controller, and an optical detection assembly. During a biological fluid processing procedure, the controller controls the operation of the pump and valve systems to separate a cell-containing fluid from the blood of a blood source and controls the optical detection assembly to emit light through the cell-containing fluid. The controller receives signals from the optical detection assembly that are indicative of the intensity of light that has passed through the cell-containing fluid. The controller receives or calculates an adjustment factor that is derived from historical data reflecting a cell collection procedure previously executed for the same blood source in which the same type of cell was collected. The controller determines an adjusted cell concentration of the cell-containing fluid based at least in part on the signals from the light detector and the adjustment factor.

A system provides for an ability to automatically identify one or more chemical components of a sample, especially a biological fluid sample, based on analysis of spectral data by at least one artificial intelligence module. The artificial intelligence module is able to be trained on a plurality of spectral data samples having known concentrations of individual chemicals and elements. The system is preferably used for spectral techniques such as UV / vis and near-infrared (NIR) spectrophotometry, but is also able to be used for other forms of spectroscopic techniques, including mass spectrometry, infrared (IR) spectrometry, X-ray spectroscopy, Raman spectrometry, or nuclear magnetic resonance (NMR) spectrometry.

The present disclosure relates generally to bioactive releasing membranes utilized with implantable devices, such as devices for the detection of analyte concentrations in a biological sample. More particularly, the disclosure relates to novel bioactive releasing membranes, to devices and implantable devices including these membranes, methods for forming the bioactive releasing membranes on or around the implantable devices, and to methods for monitoring analyte levels in a biological fluid sample using an implantable analyte detection device.

A cap with a venting plug for a biological fluid collection device is disclosed. The venting plug allows air to pass therethrough and prevents a blood sample from passing therethrough. In one embodiment, the venting plug is a porous plug. In one embodiment, the cap includes a venting plug including a carboxymethylcellulose additive. A cap that limits analyte bias due to the interaction of plasma ions with the carboxymethylcellulose by reducing the contact area between the blood and the carboxymethylcellulose additive, e.g., decreasing radius, is also disclosed.

A method for extracting at least 55% of immunoglobulin such as IgG from a biological fluid. The biological fluid containing immunoglobulin is contacted with a solid support covalently bonded to a ligand that specifically binds to immunoglobulin under conditions sufficient for non-covalent binding of immunoglobulin to the ligand. The solid support is contacted with an elution solution under conditions whereby the non-covalently bound immunoglobulin is released from the ligand and into the elution solution, wherein at least 55% of the IgG present in the biological fluid is extracted into the elution solution. The method, in some embodiments, provides a method for enriching immunoglobulin from a biological fluid comprising obtaining an initial biological fluid suspected of containing immunoglobulin and removing non-immunoglobulin components naturally occurring in the initial biological fluid to obtain a non-immunoglobulin component-reduced biological fluid.

Disclosed are methods, materials and devices for approximation of blood volume in a fluid, such as in a biological fluid collected during a surgical procedure. The method and devices may include the use of an RBC flocculant, for example polyDADMAC, and an approximate blood hematocrit from the type of animal blood being evaluated, as well as a calculated RBC packing ratio corresponding to the collection device being used. Also provided is a Blood Indicator Panel (BIP), comprising a series of markings calculated from an observed red blood settlement volume, the average animal blood hematocrit, and a calculated RBC packing ratio “η” value for the collection device. A collection device with a BIP is disclosed. Pediatric (about 200 ml or 250 ml size container), adult human (about 1,000 ml-1,500 ml) and veterinary (about 500 ml-2,500 ml) collection containers are also disclosed, that include a RBC flocculant, for use in approximating blood volume in a fluid.

The present disclosure provides apparatuses and systems for delivering a measureable absorbed-dose of a gaseous activating agent to a fluid including a biological liquid and / or cells. The apparatuses or systems include a gas-fluid contact device configured to controllably rotate or oscillate a control member having an interior surface in contact with the fluid and a control system configured to control rotation or oscillation of the contact member by the gas-fluid contact device. In some embodiments, the control system is further configured to control absorption of the gaseous activating agent by the fluid. The present disclosure also provides methods of treating a fluid including a biological liquid or cells with a gaseous activating agent to controllably activate the fluid.

The invention relates to a bag system (1) for treating a biological fluid by electromagnetic irradiation. The bag system comprises at least one element consisting of an irradiation bag (2) intended to contain the biological fluid to be irradiated. The irradiation bag (2) is made of a material permeable to the electromagnetic radiation. The bag system (1) further comprises at least one protective film (26a, 26b) covering the irradiation bag (2). The protective film (26a, 26b) is made of a gas barrier polymeric material with an oxygen permeability less than or equal to 100 cm3 / m2 / 24 at a temperature of 23 °C and a relative humidity of 50%.

This utility model is a medical device and is a disposable surgical drape for cesarean sections. The drape is made of non-woven SMS material with a density of 40–60 g / m² and integrated polyethylene elements, joined by ultrasonic welding. The standard version, a 250x160 cm canvas, contains a main 30x30 cm surgical window with a self-adhesive incision film, a drainage pocket-reservoir for collecting biological fluids, fixation elements, and an additional 30x30 cm window equipped with a folding flap made of transparent polyethylene with textile Velcro fasteners. The technical result: enabling the safe transfer of a newborn from a sterile area to the mother for early skin-to-skin contact directly during surgery, while maintaining complete asepsis of the surgical field. The device is sterile and intended for single use.

A device for mitigating sudden changes in pressure in biological fluid filtration systems is provided with a first chamber, a second chamber, a filter defining fluid communication between the first chamber and the second chamber and blocking particles of a predefined size from transferring between the first chamber and the second chamber, and a pressure spike suppression means disposed between the first chamber and an ambient environment, configured to distend outwardly when a pressure in the first chamber increases.

The present invention relates to devices comprising conjugates, and their use in depleting at least one amine, in particular ammonia, from a body fluid. The present disclosure also provides systems, apparatuses, conjugates, plurality of conjugates, and methods. More particularly, the conjugate comprises a particle bonded to at least one linker comprising a chain of n carbon atoms covalently bonded to m carbonyl groups; and at least one trapping agent A covalently bonded to the mth carbonyl group, wherein n is an integer in the range of 5 to 15, and m is an integer in the range of 5 to 10, wherein the trapping agent A is characterized by having the ability to capture or bind an amine. In some optional embodiments, the amine is at least one of methylamine, dimethylamine, or trimethylamine. In some embodiments, the linker of the conjugate of the disclosed devices comprises a straight-chain alkane and m carbonyl groups.

This invention provides a triple-coupled SERS substrate, its preparation method, and its applications. This triple-coupled SERS substrate achieves excellent signal amplification and can acquire rich SERS bands for both single and multi-component components. A robust machine learning classifier is used to identify and analyze the acquired serum metabolic Raman spectral features, demonstrating high clinical accuracy, sensitivity, and specificity in differentiating between gastrointestinal malignancies and healthy human samples. Serum metabolic analysis based on the triple-coupled SERS substrate constructed in this invention provides a promising solution to the clinical challenge of differentiating gastrointestinal malignancies and can be further expanded into clinical cancer detection based on other biological fluids.

A biological fluid information acquisition apparatus includes a light source, a prism, a first light receiving element, a second light receiving element, a differential circuit, and a signal processing unit. The prism has a first boundary face that branches a laser beam emitted from the light source into a first luminous flux and a second luminous flux, a second boundary face that totally reflects the second luminous flux, a third boundary face that totally reflects the second luminous flux reflected by the second boundary face, and a fourth boundary face emitting the second luminous flux reflected by the third boundary face, and, when a width direction of the biological fluid information acquisition apparatus is an X direction and a thickness direction of the biological fluid information acquisition apparatus orthogonal to the X direction is a Y direction, an interval between the second boundary face and the third boundary face in the Y direction is shorter than an interval between the first boundary face and the fourth boundary face in the X direction.

This invention relates to a process through which intravenous fluids, blood, or artificial blood containing high-levels of mechanically-injected dissolved oxygen can be used to maintain appropriate oxygen levels in the venous blood and thereby provide short-term oxygenation support for compromised or trauma patients. In one aspect, there is provided a system and process for oxygenating a biological fluid for use in a compromised or a trauma subject in need of oxygenation support to maintain appropriate oxygen levels in the subject, the process comprising: supplying oxygen gas from an oxygen source; and dissolving an amount of the supplied oxygen into a biological fluid to obtain an oxygen enriched biological fluid.

A biofluidic processing apparatus, a biofluidic processing system, and a method for implementing a controller to perform a biofluidic processing procedure for a blood source are disclosed. The biofluidic processing apparatus includes a pump system and a valve system, a controller, and an optical detection assembly. During the biofluidic processing procedure, the controller controls the operation of the pump system and the valve system to separate the cell-containing fluid from the blood of the blood source, and controls the optical detection assembly to emit light through the cell-containing fluid. The controller receives a signal from the optical detection assembly indicating the intensity of light passing through the cell-containing fluid. The controller receives or calculates a modulation factor derived from historical data reflecting previous cell collection procedures performed on the same blood source with the same type of cells collected. The controller determines the regulated cell concentration of the cell-containing fluid based at least in part on the signal from the photodetector and the modulation factor.

The utility model discloses a Raman spectrum detection device for freezing a biological fluid sample, and particularly relates to the technical field of biomedical detection equipment, the Raman spectrum detection device comprises a detection box, a sample table, a refrigeration device, a vacuum pump and a Raman spectrometer, the sample table is fixed in the detection box, the sample table is used for placing a sample test tube, the refrigeration device is connected with the sample table, and the vacuum pump is connected with the Raman spectrometer. The detection box is connected with the vacuum pump through a pipeline, a probe of the Raman spectrometer is fixed on the detection box, and the probe of the Raman spectrometer is used for emitting laser and collecting a Raman spectrum of the sample test tube. According to the utility model, accurate temperature regulation and control can be realized, sample denaturation and inactivation are avoided, and the spectrum quality and the detection stability are remarkably improved.

The present disclosure relates generally to bioactive releasing membranes utilized with implantable devices, such as devices for the detection of analyte concentrations in a biological sample. More particularly, the disclosure relates to drug releasing implantable devices and to methods for improved initial monitoring of analyte levels in a biological fluid sample using an implantable analyte detection device.

An improved packaging assembly for storing, distributing, treating, mixing, and dispensing tissue and / or cellular material and / or implantable material. The packaging assembly may include pouches, tubes, and a bag made of a sealable, flexible polymeric material that is open at one end and a needle-free swabable connector attached to the pouch at the other end and acting as a port to allow for the introduction or discharge of biological solutions, rinsing solution, and / or preservation solutions into the packaging assembly. The designed thickness of the wall of the packaging assembly facilitates efficient heat / cold transfer, which is useful for successful controlled rate freezing, quick thawing, and resuscitation of viable cells or tissue. The packaging assembly is also useful for combining additional biological fluids with the cellular material or tissue, and for efficient mixing of the biological fluids with the tissue and / or cellular material in the assembly.

A separation syringe assembly comprising a syringe barrel assembly and a plunger assembly, the syringe barrel assembly having an outer wall in the form of a hollow cylinder, and a cap provided at the distal end of the syringe barrel assembly; the plunger assembly providing a first plunger and a second plunger, the first plunger is a hollow barrel enclosed to form a container, the second plunger provides a cylindrical body with an open distal end and concentrically aligned outside of the first plunger. The separation syringe is configured to be rotated about the longitudinal axis and thereby separate the contents within the hollow cylinder of the syringe barrel assembly into at least two concentric annular layers.

The application relates to the technical field of intelligent health care, and discloses a biological fluid dynamics doctor-patient interaction and scheme explanation method based on a multi-modal large language model (LLM). The method is used for collecting multi-modal data such as equipment operation parameters and user physiological signals, and the multi-modal data are converted into structured descriptions through time sequence semantic coding. In combination with knowledge dynamically searched from a field knowledge base, a large language model enhanced by knowledge is driven to perform causal reasoning, and a preliminary explanation is generated. Finally, three verifications of fact checking, rule review and confidence filtering are performed to ensure the safety and reliability of the output explanation. The application solves the problems of non-transparent decision process and difficult user understanding of an intelligent hydrotherapy device, realizes credible explanation of behavior decision, and improves transparency and user experience.

The present invention relates to an in vitro method for detecting cancer in a subject, predicting clinical outcome of a subject with cancer, or monitoring treatment of a subject with cancer in vitro based on the level of tumor carbohydrate Ca10 (Ca10) measured in a biological fluid sample isolated from the subject.

The present invention relates to a cartridge (1) for analyzing biological fluids, comprising an array of channels (4, 4') that define a plurality of analysis paths. Each channel is defined by at least two opposing channel walls that define a channel height. According to the present invention, at least one channel wall has a step (M) that defines on either side thereof: a first channel segment (S1), whose walls have a first surface energy (E1) and a first elevation (e1) that defines a first channel height (h1); and a second channel segment (S2), whose walls have a second surface energy (E2) and a second elevation (e2) that defines a second channel height (h2). The first channel height (h1) and the first surface energy (E1) of the walls are greater than the second channel height (h2) and the second surface energy (E2), respectively.

Assays for detecting the level of soluble UNC5C in a biological fluid sample from a patient, and the use of such levels as markers of neurodegenerative disease presence and / or severity are described. Antibodies and fragments thereof capable of binding to UNC5C, and the use of such antibodies for detecting the level of soluble UNC5C in a biological fluid sample from a patient are also described, as well as methods for detecting the level of soluble UNC5C in a biological fluid sample from a patient using anti-UNC5C antibodies in a clinical context.

This invention discloses a method for diagnosing prostate cancer using exosome surface proteomics, aiming to address the technical problems of insufficient specificity in existing prostate-specific antigen (PSA) detection and the inability of conventional exosome analysis techniques to simultaneously achieve source specificity and proteome coverage. The method includes: collecting and preprocessing biological fluid samples; using a dual-marker orthogonal barcoding system composed of DNA aptamer probes targeting CD63 protein and prostate-specific membrane antigen, respectively, to specifically capture and enrich prostate cancer-derived exosomes; selectively labeling their surface glycoproteins, followed by cleavage and enzymatic digestion to enrich surface glycoprotein peptides; and finally, inputting the data into a diagnostic model trained based on machine learning to output diagnostic results. This invention, through the organic combination of source-specific capture and panoramic surface proteome analysis, significantly improves the specificity and sensitivity of diagnosis, providing an efficient solution for non-invasive and accurate diagnosis and invasiveness assessment of prostate cancer.